Kymera Therapeutics (NASDAQ:KYMR) Shares Down 6.7% – What’s Next?

Kymera Therapeutics, Inc. (NASDAQ:KYMR)’s share price was down 6.7% during mid-day trading on Friday . The company traded as low as $42.86 and last traded at $42.86. Approximately 150,856 shares changed hands during mid-day trading, a decline of 74% from the average daily volume of 586,785 shares. The stock had previously closed at $45.94.

Analyst Upgrades and Downgrades

KYMR has been the subject of a number of research analyst reports. Guggenheim boosted their target price on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Oppenheimer boosted their price objective on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Friday, September 27th. Wells Fargo & Company lifted their price target on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the stock an “equal weight” rating in a research report on Monday, August 12th. Leerink Partners restated an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Monday, September 9th. Finally, Morgan Stanley upped their target price on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 6th. Four analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.21.

Kymera Therapeutics Stock Performance

The company has a market cap of $2.82 billion, a P/E ratio of -18.47 and a beta of 2.21. The business’s 50-day moving average price is $47.24 and its 200 day moving average price is $41.57.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.01. The firm had revenue of $3.74 million for the quarter, compared to analyst estimates of $10.34 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business’s revenue for the quarter was down 20.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.90) earnings per share. Equities research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Insider Activity at Kymera Therapeutics

In other news, Director Pamela Esposito sold 13,500 shares of the business’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeffrey W. Albers sold 5,000 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The disclosure for this sale can be found here. 15.82% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Ameritas Investment Partners Inc. grew its position in shares of Kymera Therapeutics by 7.8% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock valued at $164,000 after buying an additional 295 shares during the last quarter. Comerica Bank raised its holdings in Kymera Therapeutics by 13.7% during the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after purchasing an additional 400 shares during the last quarter. Keudell Morrison Wealth Management lifted its position in shares of Kymera Therapeutics by 7.2% in the 2nd quarter. Keudell Morrison Wealth Management now owns 7,105 shares of the company’s stock worth $212,000 after purchasing an additional 480 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Kymera Therapeutics by 27.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after purchasing an additional 504 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Kymera Therapeutics by 8.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company’s stock worth $534,000 after buying an additional 915 shares during the period.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.